An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
NCT ID: NCT01990248
Last Updated: 2018-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
339 participants
OBSERVATIONAL
2013-03-23
2016-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
NCT01898585
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
NCT01910181
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
NCT01765543
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
NCT02143999
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
NCT03430947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of BRAF-V600 mutation-positive unresectable or metastatic melanoma confirmed by a validated test and being treated with vemurafenib
* Vemurafenib treatment must have been initiated at the time of enrollment or no more than one month prior to enrollment
* Patient (or legally acceptable representative) has personally signed and dated the informed consent document indicating that he or she has been informed of all pertinent aspects of the study, if applicable
* Patient is willing to provide information on at least one alternate contact person for study staff to contact regarding the patient's whereabouts, should the patient become lost to follow-up during the course of the study
Exclusion Criteria
* Patient has participated in any studies involving any investigational study drug within one month prior to initiating vemurafenib treatment
* Patient has any significant history of disease of medical condition (except metastatic melanoma) which in the judgment of the investigator has the potential to impact participation on the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LKH Feldkirch; Onkologie
Feldkirch, , Austria
Ordensklinikum Linz Elisabethinen ; Dermatologie
Linz, , Austria
Krankenhaus Hietzing Wien
Vienna, , Austria
ZNA Middelheim
Antwerp, , Belgium
CHIREC Edith Cavell
Brussels, , Belgium
Cliniques Universitaires St-Luc
Brussels, , Belgium
UZ Antwerpen
Edegem, , Belgium
FN Ostrava; Dermatology dep
Ostrava, , Czechia
University Hospital Prague
Prague, , Czechia
Komplexni onkologicke centrum Krajske nemocnice T. Bati, a.s. Zlin
Zlín, , Czechia
Klinikum Augsburg; Hauttumorzentrum
Augsburg, , Germany
Charite- universitatsmedizin Berlin; Med. Klinik mit Schwerpunkt Hamatologie und Onkologie
Berlin, , Germany
Ruhr-Universität Bochum; Klinik für Dermatologie und Allergologie
Bochum, , Germany
Universitatsklinikum Bonn; Klinisches Studienzentrum Klinik fur Dermatologie
Bonn, , Germany
Medizinisches Zentrum
Bonn, , Germany
Dermatologisches Zentrum am Elbe Klinikum Buxtehude
Buxtehude, , Germany
DRK Krankenhaus Chemnitz-Rabenstein; Hautkrebszentrum Chemnitz
Chemnitz, , Germany
Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik fur Dermatologie
Dresden, , Germany
Universitätsklinikum Düsseldorf; Hautklinik
Düsseldorf, , Germany
Dermatologie und Allergologie HELIOS Hauttumorzentrum Erfurt
Erfurt, , Germany
Universitatsklinikum Essen; Klinik für Dermatologie
Essen, , Germany
SRH Wald-Klinikum Gera; Zentrum fur klinische Studien (ZKS)
Gera, , Germany
Universitaetsmedizin Goettingen; Abteilung Dermato-Onkologie
Göttingen, , Germany
Universitätsmedizin Greifswald; Klinik und Poliklinik für Hautkrankheiten
Greifswald, , Germany
Univ.- Hautklinik Heidelberg
Heidelberg, , Germany
Friedrich-Schiller-Universitaet Jena; Klinik fuer Dermatologie und dermatologische Allergologie
Jena, , Germany
Klinikum Kassel GmbH; Hauttumorzentrum HTZ
Kassel, , Germany
Studienzentrum UnterEms; Onkologische Schwerpunktpraxis Leer; Dr. med. Lothar Müller
Leer, , Germany
Klinikum der Stadt Ludwigshafen am Rhein gGmbH; Hauttumorzentrum Rheinpfalz
Ludwigshafen, , Germany
UKSH Universitatsklinikum Schleswig-Holstein; Studienzentrum Dermatologie 10d
Lübeck, , Germany
Klinik und Poliklinik fur Dermatologie; Universitatsklinikum Mainz
Mainz, , Germany
Med. Fakultat Mannheim der Universitat Heidelberg; Klinik fur Dermatologie
Mannheim, , Germany
Johannes Wesling Klinikum Minden;Haut Tumor Centrum Minden
Minden, , Germany
Universitätsklinikum Münster; Klinik für Hautkrankheiten; Allgemeine Dermatologie und Venerologie
Münster, , Germany
Fachklinik Hornheide; Abteilung für Dermatologie
Münster, , Germany
Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie
Nuremberg, , Germany
Harzklinikum Dorothea Christiane Erxleben GmbH, Standort Quedlinburg; Hautkrebszentrum Harz
Quedlinburg, , Germany
Klinikum Vest; Behandlungszentrum Kanppschaftskrankenhaus Recklinghausen
Recklinghausen, , Germany
Universitätsmedizin Rostock; Klinik und Poliklinik für Dermatologie und Venerologie
Rostock, , Germany
Eberhard-Karls-Universitat Tubingen; Sektion Dermatologische Onkologie
Tübingen, , Germany
Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie
Würzburg, , Germany
Galway University Hospital; Clinical Trials Department
Galway, , Ireland
Istituto Nazionale Tumori Fondazione G. Pascale
Napoli, Campania, Italy
Policlinico S. Orsola Malpighi;Dip. Ematologia, Oncologia e Medicina di Laboratorio
Bologna, Emilia-Romagna, Italy
Ausl Ravenna-Osp.Infermi; Day Hospital Oncologia Medica
Faenza, Emilia-Romagna, Italy
Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia
Modena, Emilia-Romagna, Italy
Ospedale "Guglielmo da Saliceto";U.O. Medicina Oncologica
Piacenza, Emilia-Romagna, Italy
Azienda ASL di Rimini (Presidi di Rimini - Cattolica)) - Ospedale degli Infermi;U.O. Oncologia
Rimini, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
Milan, Lombardy, Italy
Fondazione IRCCS Policlinico San Matteo, Oncologia
Pavia, Lombardy, Italy
A.O.V.V. - P.O. di Sondrio; S.O.C. Oncologia Medica
Sondrio, Lombardy, Italy
A.U Careggi di Firenze;Oncologia
Florence, Tuscany, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, Italy
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
Siena, Tuscany, Italy
Amphia Ziekenhuis, locatie Langendijk;Oncology
Breda, , Netherlands
Academ Ziekenhuis Groningen; Medical Oncology
Groningen, , Netherlands
Atrium MC, Parkstad Heerlen; Poli Interne
Heerlen, , Netherlands
Maastricht University Medical Center,Division of Medical Oncology; Dept. Internal Medicine
Maastricht, , Netherlands
Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii
Bydgoszcz, , Poland
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
Krakow, , Poland
RegioNAlny Osrodek Onkologiczny Pododdział Diagnostyki i Terapii Onkologicznej
Lodz, , Poland
Regionalny Osrodek Onkologiczny; Oddzial Chorob Rozrostowych
Lodz, , Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej; Opolskie Centrum Onkologii
Opole, , Poland
Centrum Onkologii - Instytut, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
Warsaw, , Poland
Blekingesjukhuset; Kirurgkliniken
Karlskrona, , Sweden
Karolinska University Hospital;Department of Oncology-Pathology
Stockholm, , Sweden
Royal Sussex County Hospital
Brighton, , United Kingdom
Bristol Haematology and Oncology Centre
Bristol, , United Kingdom
Addenbrookes Hospital; Dept of Oncology
Cambridge, , United Kingdom
Velindre Cancer Centre
Cardiff, , United Kingdom
Cheltenham General Hospital; Gloucestershire Oncology Centre
Cheltenham, , United Kingdom
Dorset County Hospital NHS Foundation Trust;Research and Development/ Oncology
Dorchester, , United Kingdom
St James University Hospital
Leeds, , United Kingdom
Guys and St Thomas NHS Foundation Trust, Guys Hospital
London, , United Kingdom
St George's Hospital; Oncology
London, , United Kingdom
Imperial College Healthcare NHS Trust;Medical Oncology
London, , United Kingdom
The Clatterbridge Cancer Ctr For Oncolgy
Metropolitan Borough of Wirral, , United Kingdom
St Helens & Knowsley Trust
St Helens, , United Kingdom
New Cross Hospital; Deansley Centre
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GP28492
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.